Literature DB >> 32698857

Could the severity of COVID-19 be increased by low gastric acidity?

Elizabeth Price1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32698857      PMCID: PMC7374651          DOI: 10.1186/s13054-020-03182-0

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
Could low gastric acidity increase the risk of a severe COVID-19 illness? Although it is primarily a respiratory infection, gastrointestinal involvement from swallowed coronaviruses is reported for SARS-CoV-2 (the virus of COVID-19 [1, 2]), as well as SARS-CoV-1 [3] and MERS-CoV viruses [4]. The gastrointestinal tract may be a secondary route for spread to the lungs and other parts of the body. A possible hypothesis might be that the upper respiratory tract is attacked by viruses which are breathed in and coughed up in sputum while the lower respiratory tract is similarly infected, but is also attacked at the same time by blood-borne viruses (following translocation from a significant viral load in the gastrointestinal tract). The former might result in mild or moderate illnesses only. The latter may cause a more severe illness, as the lungs are being attacked by viruses coming from two routes simultaneously. Although it can be transiently higher, the pH of normal gastric acid is generally between 1.5 and 3.5. The SARS-CoV-1 virus is inactivated at a pH < 3.0 and > 12.0 [5]. Assuming these inactivation levels are similar for SARS-CoV-2, gastric acid will not inhibit all the viruses in the stomach (and some viruses will be hidden in food boluses). However, the inhibition that does occur may be enough to decrease the viral load entering the small intestine. In many older adults, the gastric acid pH is higher than normal, either because of atrophic gastritis or because of antacid and acid-reducing medications. One oral dose of a proton pump inhibitor raises the gastric acid pH from 2.0 to over 6.0, which will not inhibit the virus [6]. (For MERS-CoV, treatment with a proton pump inhibitor in an animal model resulted in exaggerated infection in the small intestine [4].) In a study of 204 COVID-19 patients, fever or respiratory symptoms were generally present but 50% also reported digestive symptoms, particularly appetite loss and diarrhoea [1]. In a literature search, abdominal pain was associated with a near fourfold increased odds of severe disease, possibly because of a high viral load, viral replication in the gut and viremia [2]. Children rarely suffer from severe illnesses with COVID-19. As well as protection related to immunological factors and possible differences in the ACE2 receptor concentrations in their lungs, children (other than infants) generally have good levels of gastric acid. This may provide some protection from swallowed viruses, even though young children usually swallow their sputum rather than spit it out. To determine whether gastric acid gives some protection from COVID-19, the amount of antacids and acid-reducing drugs used by patients with severe infections could be compared with the amount used by patients with mild or no disease. It should not be overlooked that many of these medications may be purchased over-the-counter and be taken only occasionally for gastrointestinal symptoms, rather than being prescribed by a medical practitioner. Therefore, they may not appear on a list of a patient’s usual medications. Whether there is any relation between taking these drugs and the clinical course could be considered. Drugs taken during hospital admissions should also be recorded, as hospitals may continue medications taken at home. In addition, many intubated patients are given acid-reducing drugs and gastrointestinal feeding may be continuous rather than intermittent. Such factors could result in a gastric pH of around 4.0 or 5.0. This would not inactivate these viruses, which might then pass into the small intestine where the relevant ACE2 receptors are abundant. If there is evidence for some protection by gastric acidity, stopping antacids and acid-reducing medications could be considered, particularly at times when patients are at increased risk.
  6 in total

Review 1.  The impact of proton pump inhibitors on the human gastrointestinal microbiome.

Authors:  Daniel E Freedberg; Benjamin Lebwohl; Julian A Abrams
Journal:  Clin Lab Med       Date:  2014-09-24       Impact factor: 1.935

2.  Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases.

Authors:  Xueying Shi; Encong Gong; Dongxia Gao; Bo Zhang; Jie Zheng; Zifen Gao; Yanfeng Zhong; Wanzhong Zou; Bingquan Wu; Weigang Fang; Songlin Liao; Shenglan Wang; Zhigang Xie; Min Lu; Lin Hou; Haohao Zhong; Hongquan Shao; Ning Li; Congrong Liu; Fei Pei; Jingping Yang; Yuping Wang; Zhihui Han; Xiaohong Shi; Qianying Zhang; Jiangfeng You; Xiang Zhu; Jiang Gu
Journal:  Am J Gastroenterol       Date:  2005-01       Impact factor: 10.864

3.  Implications of gastrointestinal manifestations of COVID-19.

Authors:  Lijing Yang; Lei Tu
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05-12

4.  Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus.

Authors:  Jie Zhou; Cun Li; Guangyu Zhao; Hin Chu; Dong Wang; Helen Hoi-Ning Yan; Vincent Kwok-Man Poon; Lei Wen; Bosco Ho-Yin Wong; Xiaoyu Zhao; Man Chun Chiu; Dong Yang; Yixin Wang; Rex K H Au-Yeung; Ivy Hau-Yee Chan; Shihui Sun; Jasper Fuk-Woo Chan; Kelvin Kai-Wang To; Ziad A Memish; Victor M Corman; Christian Drosten; Ivan Fan-Ngai Hung; Yusen Zhou; Suet Yi Leung; Kwok-Yung Yuen
Journal:  Sci Adv       Date:  2017-11-15       Impact factor: 14.136

5.  Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV.

Authors:  Miriam E R Darnell; Kanta Subbarao; Stephen M Feinstone; Deborah R Taylor
Journal:  J Virol Methods       Date:  2004-10       Impact factor: 2.014

6.  Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis.

Authors:  Brandon Michael Henry; Maria Helena Santos de Oliveira; Justin Benoit; Giuseppe Lippi
Journal:  Intern Emerg Med       Date:  2020-04-17       Impact factor: 3.397

  6 in total
  7 in total

1.  Direct and indirect effects of SARS-CoV-2 on wastewater treatment.

Authors:  Termeh Teymoorian; Targol Teymourian; Elaheh Kowsari; Seeram Ramakrishna
Journal:  J Water Process Eng       Date:  2021-06-25

Review 2.  SARS-CoV-2-associated gastrointestinal and liver diseases: what is known and what is needed to explore.

Authors:  Dina Sweed; Eman Abdelsameea; Esraa A Khalifa; Heba Abdallah; Heba Moaz; Inas Moaz; Shimaa Abdelsattar; Nadine Abdel-Rahman; Asmaa Mosbeh; Hussein A Elmahdy; Eman Sweed
Journal:  Egypt Liver J       Date:  2021-07-31

3.  Reduced gastric acidity, proton pump inhibitors and increased severity of COVID-19 infections.

Authors:  Elizabeth Price; David F Treacher
Journal:  Crit Care       Date:  2021-02-18       Impact factor: 9.097

4.  Inflammation at the crossroads of Helicobacter pylori and COVID-19.

Authors:  Ileana Gonzalez; Cristian Lindner; Ivan Schneider; Miguel A Morales; Armando Rojas
Journal:  Future Microbiol       Date:  2021-12-17       Impact factor: 3.165

5.  A case of COVID-19 diarrhea relieved by bile acid sequestrant administration.

Authors:  Akira Shirohata; Ryusuke Ariyoshi; Seiji Fujigaki; Katsuhide Tanaka; Teruhisa Morikawa; Tsuyoshi Sanuki; Yoshikazu Kinoshita
Journal:  Clin J Gastroenterol       Date:  2022-02-04

Review 6.  The Effects of Vitamins and Micronutrients on Helicobacter pylori Pathogenicity, Survival, and Eradication: A Crosstalk between Micronutrients and Immune System.

Authors:  Ali Nabavi-Rad; Mahsa Azizi; Shaghayegh Jamshidizadeh; Amir Sadeghi; Hamid Asadzadeh Aghdaei; Abbas Yadegar; Mohammad Reza Zali
Journal:  J Immunol Res       Date:  2022-03-16       Impact factor: 4.818

Review 7.  Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic.

Authors:  Nadezhda Ivanova; Yoana Sotirova; Georgi Gavrailov; Krastena Nikolova; Velichka Andonova
Journal:  Pharmaceutics       Date:  2022-02-27       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.